An increasingly favourable environment allows SHIMADZU to improve to Neutral
The independent financial analyst theScreener just upgraded the general evaluation of SHIMADZU (JP), a company active in the Medical Equipment industry. As regards its fundamental valuation, the title confirms its rating of 2 out of 4 stars while its market behaviour remains as moderately risky. theScreener believes, however, that a more enabling environment allows the title to increase its general evaluation to Neutral. As of the analysis date February 15, 2022, the closing price was JPY 4,175.00 and its expected value was estimated at JPY 4,344.36.Shimadzu is a manufacturing company. Co. is engaged in the provision of R&D, manufacturing, sales and maintenance services in measuring business, medical equipment, aircraft equipment, industrial equipment and other business fields. Co. offers optical measuring equipment, surface measuring equipment, observation instruments, mass spectrometers, bioreagents, laser equipment; x-ray diagnostic equipment, diagnostic nuclear medicine equipment, radiation therapy equipment and medical information systems; space related equipment and aeroplanes electronic devices; magnetic equipment, solar battery devices and LCD panel products, among others. Co. is also engaged in real estate leasing.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.